Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in cr1

HIGHLIGHTS

• who: Lijie Han from the Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China have published the paper: Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1, in the Journal: (JOURNAL)
• what: The authors explored the role of MRD1-3 in directing the selection of PRT for patients with de novo IR-AML in CR1, although the selection for transplant was dependent on MRD status and donor availability. The authors demonstrated that MRD3-positive patients (i.e., after the third . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.